Advertisement

S. Vincent Rajkumar, MD, on Cost-Effective Treatment of Multiple Myeloma

First International Summit on Interventional Pharmacoeconomics

Advertisement

Related Videos

Boon-Cher Goh, MD, on Cancer Drugs in Singapore: 3As (Availability, Accessibility, and Affordability)

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Garth Strohbehn, MD, MPhil, on Applied Clinical Pharmacology in a Crisis: Interventional Pharmacoeconomics and COVID-19

Matthew Seymour, MD: A Clinical Trialist’s Perspective

Advertisement

Advertisement

Sep

18

Today In Oncology

Cancer-Induced Nerve Injury Identified as Driver of PD-1 Resistance Across Tumor Types

Study Finds Postapproval Cancer Trials Fell After Inflation Reduction Act

Incorporating Family Caregivers Into Shared Decision-Making for Patients With Cancer

Clear-Margin Diagnostic Excisional Biopsy May Adequately Treat Melanoma in Situ, Study Finds

Is TBI Associated With Malignant Brain Tumors

Advertisement

© 2025 HSP News Service, L.L.C.